全文获取类型
收费全文 | 39590篇 |
免费 | 3637篇 |
国内免费 | 1706篇 |
专业分类
耳鼻咽喉 | 811篇 |
儿科学 | 290篇 |
妇产科学 | 741篇 |
基础医学 | 3413篇 |
口腔科学 | 602篇 |
临床医学 | 2854篇 |
内科学 | 3595篇 |
皮肤病学 | 437篇 |
神经病学 | 455篇 |
特种医学 | 2305篇 |
外国民族医学 | 53篇 |
外科学 | 6742篇 |
综合类 | 6394篇 |
现状与发展 | 9篇 |
预防医学 | 694篇 |
眼科学 | 243篇 |
药学 | 1548篇 |
4篇 | |
中国医学 | 396篇 |
肿瘤学 | 13347篇 |
出版年
2024年 | 39篇 |
2023年 | 492篇 |
2022年 | 739篇 |
2021年 | 1496篇 |
2020年 | 1322篇 |
2019年 | 1178篇 |
2018年 | 1135篇 |
2017年 | 1234篇 |
2016年 | 1493篇 |
2015年 | 1791篇 |
2014年 | 2416篇 |
2013年 | 2054篇 |
2012年 | 2100篇 |
2011年 | 2409篇 |
2010年 | 2115篇 |
2009年 | 2214篇 |
2008年 | 2300篇 |
2007年 | 2444篇 |
2006年 | 2298篇 |
2005年 | 2023篇 |
2004年 | 1732篇 |
2003年 | 1548篇 |
2002年 | 1358篇 |
2001年 | 1245篇 |
2000年 | 1049篇 |
1999年 | 835篇 |
1998年 | 749篇 |
1997年 | 622篇 |
1996年 | 446篇 |
1995年 | 365篇 |
1994年 | 320篇 |
1993年 | 224篇 |
1992年 | 194篇 |
1991年 | 152篇 |
1990年 | 124篇 |
1989年 | 87篇 |
1988年 | 92篇 |
1987年 | 79篇 |
1986年 | 71篇 |
1985年 | 73篇 |
1984年 | 58篇 |
1983年 | 41篇 |
1982年 | 43篇 |
1981年 | 37篇 |
1980年 | 32篇 |
1979年 | 28篇 |
1978年 | 17篇 |
1977年 | 12篇 |
1976年 | 3篇 |
1975年 | 4篇 |
排序方式: 共有10000条查询结果,搜索用时 171 毫秒
991.
992.
993.
Graham H. Litchman Alison L. Fitzgerald Sarah J. Kurley Robert W. Cook Darrell S. Rigel 《Current medical research and opinion》2020,36(8):1295-1300
AbstractObjective: To determine how results from a prognostic 40-gene expression profiling (40-GEP) test would impact clinician management decisions and how their choices would align with a National Comprehensive Cancer Network (NCCN) compliant, risk-directed management plan for high-risk cutaneous squamous cell carcinoma (cSCC).Methods: Clinicians attending a national dermatology conference were presented with 40-GEP test validation data. They were asked to rate clinicopathological features and molecular test results to assess their opinion of how concerning each is to cSCC prognosis. When presented with vignettes describing patients with NCCN-defined high-risk features, clinicians were asked to select a treatment plan using pre-test (no 40-GEP results), then, post-test (40-GEP Class 1, 2A, or 2B results) methodology along with corresponding metastasis rates for each test group.Results: Risk factors deemed of highest concern for metastatic outcomes were a Class 2B 40-GEP result, perineural invasion, immunosuppression, invasion beyond subcutaneous fat, and tumor diameter >1?cm on the scalp. When presented with a 40-GEP result that indicated reduced risk of metastasis (Class 1), clinicians altered their treatment management plan accordingly. Specifically, there was significant reduction in the recommendations for sentinel lymph node biopsy, adjuvant radiation or chemotherapy, follow-up time, and nodal imaging. By comparison, when a 40-GEP result indicated an increased risk of metastasis (Class 2B), significant risk-appropriate increases in management intensity was observed for the aforementioned clinical decisions.Conclusion: Integration of 40-GEP results impacted management decisions in a significant and risk-appropriate manner for high-risk cSCC patient scenarios, while remaining aligned with national guidelines for patient management. 相似文献
994.
《The British journal of oral & maxillofacial surgery》2019,57(9):847-856
This is the third of three articles that give an overview of the current evidence for management of the neck and parotid in patients with cutaneous cancers of the head and neck. In this paper we discuss Merkel cell carcinoma (MCC) and review the latest evidence for management of the regional nodes. 相似文献
995.
996.
997.
近年来,免疫治疗不断发展,免疫检查点抑制剂联合颅内放疗治疗黑色素瘤脑转移的安全性和有效性已得到初步认可,但免疫检查点抑制剂联合颅内放疗治疗肺癌脑转移是否产生类似的协同作用尚未达成共识,免疫检查点抑制剂与颅内放疗联合的最佳时机、联合治疗的获益人群等也需进一步探讨。本文主要就肺癌脑转移患者颅内放疗联合免疫检查点抑制剂的研究进展进行综述。 相似文献
998.
目的探讨前列腺癌并阴茎转移的发病机制、临床特征及诊疗预后。
方法回顾性分析1例前列腺癌并阴茎转移患者的临床资料。
结果患者68岁,因排尿困难在我院行经尿道前列腺电切术,术后病理检查报告为前列腺腺癌。术后行外放射治疗及内分泌治疗,15个月后发生阴茎转移,予以个体化的治疗方案后前列腺癌特异性抗原下降,阴茎肿块缩小,不适症状缓解。
结论前列腺癌阴茎转移发生罕见且预后差,有多种转移机制参与;手术及放化疗虽为姑息性治疗,但个体化的治疗方案可延缓疾病进展,改善患者生活质量。 相似文献
999.
1000.
Aaron S. Farberg Mary A. Hall Leah Douglas Kyle R. Covington Sarah J. Kurley Robert W. Cook 《Current medical research and opinion》2020,36(8):1301-1307
AbstractObjective: To integrate gene expression profiling into the management of high-risk cutaneous squamous cell carcinoma (cSCC) within the National Comprehensive Cancer Network (NCCN) guidelines to improve risk-aligned management recommendations.Methods: A cohort of 300 NCCN-defined high-risk cSCC patients, along with the American Joint Committee on Cancer (AJCC) T stage, Brigham and Women’s Hospital (BWH) T stage, and known patient outcomes were analyzed. Risk classifications using a validated 40-gene expression profile (40-GEP) test and T stage were applied to NCCN patient management guidelines. Risk-directed patient management recommendations within the NCCN guidelines framework were aligned based on risk for metastasis.Results: Of the 300 NCCN high-risk cSCC patients, 159 (53.0%) were 40-GEP Class 1 and AJCC T1-T2, and 173 (57.7%) were Class 1 and BWH T1-2a, indicating low risk for metastasis and, thereby, suggesting low management intensity. The 40-GEP integration suggested high intensity management for only 24 (8.0%) patients (all Class 2B), and moderate intensity management for the remainder of the cohort.Conclusions: The 40-GEP test can be integrated within existing NCCN guideline recommendations for managing cSCC patients to help refine risk-directed management decisions. Integration of the 40-GEP test would allow >50% of this NCCN-defined high-risk cohort to be managed with the lowest intensity recommendations within the broad NCCN guidelines. High intensity management was deemed risk-appropriate for a small subpopulation (8.0%). This study demonstrates that the 40-GEP test, in combination with T stage, has clinical utility to impact patient management decisions in NCCN high-risk cSCC for improving risk-aligned management within the NCCN guidelines framework. 相似文献